Shifting the Paradigm in the Management of Beta-Thalassemia: Transitioning to a Young Adult
July 21, 2022
July 21, 2023
Scroll to the Bottom of this Information to Begin this Course
This activity is jointly provided by EXCEL Continuing Education.
This activity is supported by independent education grants from AGIOS PHARMACEUTICALS and CHIESI GLOBAL RARE DISEASES.
- Physicians — maximum of 1.0 AMA PRA Category 1 Credit(s)™
- Nurses — 1.0 Contact Hours
All other healthcare professionals completing this course will be issued a statement of participation.
This activity is designed to meet the educational needs of physicians, nurse practitioners, and other healthcare professionals who treat and/or manage patients with beta-thalassemia or who wish to increase their knowledge and competence regarding this genetic disease.
Thalassemias are a common cause of hypochromic microcytic anemia which arises from the reduced or absent synthesis of the globin chain of hemoglobin. This global chain imbalance eventually advances to iron overload leading to infections, fatigue, weakness, and even organs that do not function properly. This educational initiative intends to close β‑thalassemia clinical care gaps when transitioning patient care from pediatrics into adulthood, as well as improving awareness of non-transfusion dependent treatments once patients age into adulthood, while gaining a better understanding of the patient’s journey and the impact this transition can have on treatment outcomes.
Upon completion of this activity, participants should be better able to:
- Assess genotype-phenotype correlations, disease severity and considerations for monitoring, using sample patient case scenarios
- Recognize that β‑thalassemia has 2 major classifications: transfusion-dependent thalassemia (TDT) and non-transfusion-dependent thalassemia (NTDT)
- Identify the management barriers and needs of young adults with β-thalassemia when transitioning to adult academic and community treatment centers
- Discuss existing and emerging treatments for β‑thalassemia and how these therapies may be safely and effectively integrated into practice to deliver high quality care
Jeanne Boudreaux, MD
Aflac Cancer & Blood Disorders Center
Emory University, Children’s Healthcare of Atlanta
Associate Professor of Pediatrics
Director of the Comprehensive Thalassemia Program
Clinical Director of General Hematology
Atlanta, GA, USA
Kevin H.M. Kuo, MD, MSc, FRCPC
Clinician-Investigator and Staff Hematologist
Red Blood Cell Disorders Program, Division of Medical Oncology and Hematology, Department of Medicine, University Health Network
Associate Professor, Division of Hematology, Department of Medicine, Faculty of Medicine
Assistant Professor (status), Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health
University of Toronto
Toronto, Ontario, Canada
Physician Accreditation Statement
EXCEL Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Physician Credit Designation
EXCEL Continuing Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The UEMS-EACCME® = European Union of Medical Specialists and European Accreditation Council for CME have mutual recognition agreements with the American Medical Association for live events and e-learning materials. European physicians can earn their ECMEC®s (European CME credits) by either attending a live presentation approved by an ACCME accredited provider such as EXCEL or participating in e-learning activities (on-demand webcasts) from accredited providers from the USA that have been certified for AMA PRA Category 1 Credits™.
Disclosures of Conflicts of Interest
- Jeanne Bourdreaux, MD
- Data Safety Monitoring Board: Chiesi / ApoPharma, BlueBird Bio
- Advisory Board: Celgene, Acelleron, Bristol Myers Squibb
- Kevin H.M. Kuo, MD
- Grant Support: Pfizer
- Consultant: Agios, Alexion, Apellis, Aruvant, Bluebirdbio, Celgene/BMS, Forma, Novartis, and Pfizer
- Honorarium: Agios, Alexion, Apellis, Bluebirdbio, Celgene/BMS, Forma
- Data Safety Monitoring Board: Bioverativ/Sanofi and Sangamo
- Scientific Collaboration: Phoenicia Biosciences
EXCEL staff and Peer Reviewer: Nothing to disclose
Instructions for Participation and Credit
There are no fees for participating and receiving CPEU credit for this enduring activity. To receive CME credit participants must:
- Read the CME/CE information and faculty disclosures.
- Participate in the online activity.
- Submit the evaluation form.
Certificates will be emailed to the participant.
Course Viewing Requirements
Internet Explorer 8.0+ for Windows 2003, Vista, XP, Windows 7, Windows 8.1 and above
Google Chrome 28.0+ for Windows, Mac OS, or Linux
Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux
Safari 6.0+ for Mac OSX 10.7 and above
Supported Phones & Tablets:
Android 4.0.3 and above
iPhone/iPad with iOS 6.1 or above
Disclosure of Unlabeled Use
EXCEL Continuing Educaton requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
For CME questions please contact: email@example.com.